Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F13%3A%230000739" target="_blank" >RIV/00064190:_____/13:#0000739 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.
Original language description
A long-term 5-year study investigating whether tocilizumab (study drug) continues to be safe and effective in patients with moderate to severe rheumatoid arthritis (RA) who have completed participation in one of the tocilizumab short-term core studies
Czech name
—
Czech description
—
Classification
Type
V<sub>souhrn</sub> - Summary research report
CEP classification
FP - Other medical fields
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2013
Confidentiality
U - Předmět řešení projektu je utajovanou skutečností podle zvláštních právních předpisů nebo je skutečností, jejíž zveřejnění by mohlo ohrozit činnost zpravodajské služby. Údaje o projektu jsou upraveny tak, aby byly zveřejnitelné
Data specific for result type
Number of pages
1
Place of publication
Praha
Publisher/client name
MKS Research, s.r.o.
Version
—